Meihua International Medical Technologies Co (MHUAF) Fair Value & Analysis
Healthcare · US · Market cap $7.1M
Meihua International Medical Technologies Co
MHUAF · US
Fair value as of: Jul 18, 2026
From 21 valuation models · updated today
Share price −19.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $2.05 – $48.40 · fair‑value band $4.33 – $8.04 · the $6.75 price screens above the $6.18 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Meihua International Medical Technologies Co (MHUAF) currently trades at $6.75, while our model-based Fair Value estimate is $6.18, implying the stock looks roughly 8.4% fairly valued today. We read business quality at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Meihua International Medical Technologies Co generated revenue of $61.8M at a net margin of 11.0%. Revenue declined 53.8% year over year. It earns a return on equity of 3.9%. The balance sheet holds a net cash position of $6.2M. Fundamentals as of Jul 18, 2026
Our scenario range runs from $4.33 (bear case) to $8.04 (bull case); at $6.75, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside, at -8%, MHUAF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Meihua International Medical Technologies Co., Ltd. engages in the research and development, manufacture, and sale of medical devices in the People's Republic of China, Europe, North America, South America, Asia, Africa, and Oceania. The company offers Class I disposable medical devices, including disposable medical X-ray films, medical dry films, dry laser imagers, gauze bandages, examination gloves, pharmaceutical packaging materials and containers, low-density polyethylene bottles for eye drops, and high-density polyethylene bottles for tablets; Class II products, such as disposable full anesthesia kits, medical brush, woman's examination kits, urethral catheterization kits, disposable bracelet, tube cleaning brush, gynecological examination and sterile surgical dressing kits, medical hand scrub, cervical sampling swab, catheter, hand washing brush, cervical liquid based cell sampler, surgical hats, suction connecting tube, nasal oxygen tube, endotracheal intubation, medical …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Meihua International Medical Technologies Co reported revenue of $61.8M in FY2025 versus $104M in FY2021, a compound −12.2%/yr. Reported net income was $6.8M in FY2025, compounding −24.6%/yr from FY2021.
Is MHUAF fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | C$20.93 | C$9.25 | -56% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Becton, Dickinson and Company BDX | $140.71 | $104.17 | -26% |
| Alcon Inc ALC | CHF 52.10 | CHF 35.34 | -32% |
| ResMed Inc RMD | $191.26 | $187.89 | -2% |
| West Pharmaceutical Services, Inc WST | $329.71 | $137.28 | -58% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Meihua International Medical Technologies Co (MHUAF) undervalued?
What is the fair value of MHUAF?
What is the quality score of MHUAF?
What is the revenue of Meihua International Medical Technologies Co (MHUAF)?
What is the net profit margin of MHUAF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Meihua International Medical Technologies Co analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.